Investor Presentaiton

CSL Vifor Iron Nephrology Revenue¹ $m 505 Major Brands ferinject® ferric carboxymaltose Venofer iron sucrose injection, USP MIRCERA VELPHORO® eyelet Highlights China FERINJECTⓇ inclusion in the National Reimbursement Drug List Well prepared for a transitioning iron market US step edit pressure MIRCERAⓇ • Strong ESA performance in the U.S., as patients convert KAPRUVIAⓇ Dialysis 399 3 Retacrit pala-p KAPRUVIA 5 Non-Dialysis 90 Veltassa TAVNEOS™ (avacopan) All Other Total 17 1,011 • Approved in multiple emerging markets • Strong performance in Germany, France and Austria VELPHORO® • . US inventory adjustment China approval and inclusion in the National Reimbursement Drug List Strong TAVNEOS® performance in all EU launch markets, with regulatory approval obtained in South Korea Paediatric indication of VELTASSAⓇ in US Oct-23, EU Jan-24 1. The prior comparable period included only 5 months revenue following the acquisition of Vifor Pharma in August 2022. 2. Licensed from F. Hoffman-La Roche AG; 3. Licensed from Pfizer Inc.; 4. Licensed from Cara Therapeutics, Inc.;5. Ex-US rights licensed from ChemoCentryx, Inc., a wholly owned subsidiary of Amgen, Inc. 9 Driven by Our Promise CSL

View entire presentation